Cadonilimab plus anlotinib effectively relieve rare cardiac angiosarcoma with multiple metastases: a case report and literature review

Holzhauser L, Heymer J, Kasner M, Landmesser U, Skurk C (2015) Rare case of a multilocular primary cardiac intimal sarcoma presenting as left atrial mass with new onset atrial fibrillation. Eur Heart J 36(35):2402. https://doi.org/10.1093/eurheartj/ehv215 Campanile A, Tavazzi G, Alam MH et al (2016) An unexpected finding in an asymptomatic patient with atrial fibrillation: CA. Lancet 387(10036):e29. https://doi.org/10.1016/S0140-6736(16)00086-6 Igarashi Y, Sasada T (2020) Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res 2020:5825401. https://doi.org/10.1155/2020/5825401 Urbini M, Astolfi A, Indio V et al (2020) Genetic aberrations and molecular biology of cardiac sarcoma. Ther Adv Med Oncol 12:1758835920918492. https://doi.org/10.1177/1758835920918492 Brennan MF, Antonescu CR, Moraco N, Singer S (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260(3):416–421. https://doi.org/10.1097/SLA.0000000000000869. (discussion 421–2) Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590 Dajsakdipon T, Siripoon T, Ngamphaiboon N, Ativitavas T, Dejthevaporn T (2022) Immunotherapy and biomarkers in sarcoma. Curr Treat Options Oncol 23(3):415–438. https://doi.org/10.1007/s11864-022-00944-6 Antonescu C (2014) Malignant vascular tumors—an update. Mod Pathol 27(Suppl 1):S30–S38. https://doi.org/10.1038/modpathol Khan JA, Maki RG, Ravi V (2018) Pathologic angiogenesis of malignant vascular sarcomas: implications for treatment. J Clin Oncol 36(2):194–201. https://doi.org/10.1200/JCO.2017.74.9812 Nizam A, Paquette EL, Wang BG, Aragon-Ching JB (2018) Epithelioid angiosarcoma of the bladder: a case report and review of the literature. Clin Genitourin Cancer 16(6):e1091–e1095. https://doi.org/10.1016/j.clgc.2018.07.010 Florou V, Wilky BA (2021) Current management of angiosarcoma: recent advances and lessons from the past. Curr Treat Options Oncol 22(7):61. https://doi.org/10.1007/s11864-021-00858-9 Cao J, Wang J, He C, Fang M (2019) Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res 9(11):2303–2313 O’Donovan C, Davern M, Donlon NE, Lysaght J, Conroy MJ (2021) Chemokine-targeted therapies: an opportunity to remodel immune profiles in gastro-oesophageal tumours. Cancer Lett 521:224–236. https://doi.org/10.1016/j.canlet.2021.09.005 Yao W, Du X, Wang J, Wang X, Zhang P, Niu X (2022) Long-term efficacy and safety of anlotinib as a monotherapy and combined therapy for advanced sarcoma. Onco Targets Ther 15:669–679. https://doi.org/10.2147/OTT.S365506 Ropp AM, Burke AP, Kligerman SJ, Leb JS, Frazier AA (2021) Intimal sarcoma of the great vessels. Radiographics 41(2):361–379. https://doi.org/10.1148/rg.2021200184 Zhu MMT, Shenasa E, Nielsen TO (2020) Sarcomas: immune biomarker expression and checkpoint inhibitor trials. Cancer Treat Rev 91:102115. https://doi.org/10.1016/j.ctrv.2020.102115 Hod N, Shalev A, Levin D, Anconina R, Ezroh Kazap D, Lantsberg S (2018) FDG PET/CT of CA with pulmonary metastases. Clin Nucl Med 43(10):744–746. https://doi.org/10.1097/RLU.0000000000002215 Naruse G, Kawasaki M, Yanase K, Tanaka T (2020) Primary angiosarcoma in the right atrium diagnosed by a cardiac tumor biopsy using intracardiac echocardiography. J Med Ultrasound 28(2):120–122. https://doi.org/10.4103/JMU.JMU_93_19 Hendriksen BS, Stahl KA, Hollenbeak CS et al (2019) Postoperative chemotherapy and radiation improve survival following cardiac sarcoma resection. J Thorac Cardiovasc Surg. https://doi.org/10.1016/j.jtcvs.2019.10.016 Li X, Lan L, Hu H (2022) Case report: primary CA with multiple metastases. Front Cardiovasc Med 28(9):941967. https://doi.org/10.3389/fcvm.2022.941967 Donmez AA, Cekmecelioglu D, Adademir T, Yilmaz E, Alp HM (2018) Primary CA with rare presenting feature and successful surgical treatment. Braz J Cardiovasc Surg 33(5):525–527. https://doi.org/10.21470/1678-9741-2017-0239 Berry MF, Williams M, Welsby I, Lin S (2010) CA presenting with right coronary artery pseudoaneurysm. J Cardiothorac Vasc Anesth 24(4):633–635. https://doi.org/10.1053/j.jvca.2009.04.002 Wang C, Shi M, Yang C, Ma T, Jiang J, Liu Y, Xi W, Zhu Z, Zhang J (2017) Comprehensive treatment of unresectable CA: a case report and review of literature. Mol Clin Oncol 7(5):859–863. https://doi.org/10.3892/mco.2017.1390 Mangla A, Gupta A, Mansur DB, Abboud S, Rothermel LD, Oliveira GH (2021) Right atrial CA treated with concurrent proton beam therapy and paclitaxel: a novel approach to a rare disease. Thorac Cancer 12(7):1131–1133. https://doi.org/10.1111/1759-7714.13895 Honda Y, Otsuka A, Ono S et al (2016) Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 6(1):e1253657. https://doi.org/10.1080/2162402X.2016.1253657 Hofer S, Zeidler K, Schipf A, Kempf W, Zimmermann D, Aebi S (2018) Angiosarcoma of the scalp responding to nivolumab: a case report. Br J Dermatol 179(2):530–531. https://doi.org/10.1111/bjd.16698 Constantinidou A, Sauve N, Stacchiotti S et al (2020) Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open 5(4):e000787. https://doi.org/10.1136/esmoopen-2020-000787 D’Angelo SP, Mahoney MR, Van Tine BA et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416–426. https://doi.org/10.1016/S1470-2045(18)30006-8 Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS (2017) Angiosarcoma treated successfully with anti-PD-1 therapy—a case report. J Immunother Cancer 5(1):58. https://doi.org/10.1186/s40425-017-0263-0 Vasella M, Gousopoulos E, Guidi M et al (2022) Targeted therapies and checkpoint inhibitors in sarcoma. QJM 115(12):793–805. https://doi.org/10.1093/qjmed/hcab014 Kelly CM, Antonescu CR, Bowler T et al (2020) Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol 6(3):402–408. https://doi.org/10.1001/jamaoncol.2019.6152 D’Angelo SP, Richards AL, Conley AP et al (2022) Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun 13(1):3477. https://doi.org/10.1038/s41467-022-30874-8 Liu Z, Gao S, Zhu L et al (2021) Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: a retrospective multiple institution study. Cancer Med 10(21):7593–7600. https://doi.org/10.1002/cam4.4286 Mai H, Lin S, Chen D et al (2021) 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. J ImmunoTherapy Cancer. https://doi.org/10.1136/jitc-2021-SITC2021.436 Li J, Cao P, Chen Y et al (2022) Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment. Exp Cell Res 417(1):113197. https://doi.org/10.1016/j.yexcr.2022.113197 Painter CA, Jain E, Tomson BN et al (2020) The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 26(2):181–187. https://doi.org/10.1038/s41591-019-0749-z Mehnert JM, Panda A, Zhong H et al (2016) Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126(6):2334–2340. https://doi.org/10.1172/JCI84940